Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (December 2025)
32 slides from Immunome's investor presentation, Dec 15, 2025
Slide 1: Corporate Presentation: Transformative Targeted Therapeutics
Corporate Presentation Transformative Targeted Therapeutics December 2025 Exhibit 99.2
Slide 2: Disclosures
Disclosures For purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question-and-answer session that follows that oral pres
Slide 3: Establishing a Premier Targeted Oncology Company
Establishing a Premier Targeted Oncology Company i Varegacestat, an oral, once-daily gamma secretase inhibitor for the treatment of desmoid tumors, with positive Phase 3 topline data NDA submission planned for 2Q 2026 Positioned to be a best-in-class option Deep expertise in ADCs driving differentia
Slide 4: Broad Portfolio of Targeted Oncology Therapeutics
Broad Portfolio of Targeted Oncology Therapeutics Program Target / Modality Preclinical Phase 1 Phase 2 Phase 3 Commercial Next Anticipated Milestone Varegacestat Gamma Secretase Inhibitor NDA Submission | 2Q 2026 IM-1021 ROR1 ADC Initial Lymphoma Data | 2026 IM-3050 FAP Radiotherapy First Patient I
Slide 5: Varegacestat: Oral, Once-Daily Gamma Secretase Inhibitor
Varegacestat Phase 3 Oral, Once-Daily Gamma Secretase Inhibitor
Slide 6: Varegacestat Demonstrated Exceptional Results For Patients
Generally well-tolerated with manageable safety profile Confirmed Objective Response Rate2: 56% Progression-Free Survival1: Hazard Ratio 0.16 (p<0.0001) Median Best Tumor Volume Reduction3: 83% (1) Primary endpoint (2) Key secondary endpoint (3) Exploratory endpoint 2Q26 NDA Submission Planned Vareg
Slide 7: Desmoid Tumors are Locally Aggressive & Debilitating
Desmoid tumors often strike in young adulthood, with 1,000-1,650 patients diagnosed each year and 10-11,000 actively managed patients in the US1 Can lead to debilitating pain, deformity, and life-threatening organ damage depending on location1 Quality of life is a major challenge with a majority of
Slide 8: Varegacestat is a Gamma Secretase Inhibitor with a Differentiated Pharmacokinetic Profile
Varegacestat is a Gamma Secretase Inhibitor with a Differentiated Pharmacokinetic Profile Desmoid tumors are driven by nuclear accumulation of β-CATENIN resulting from cross-talk between WNT and NOTCH pathways2 Kasper et al. Sources: (1) Figure adapted from Kasper et al., ESMO 2022. Abstr LBA2, base
Slide 9: RINGSIDE is the Largest Phase 3 Study in Desmoid Tumors
Key Inclusion Criteria Progressed within last 12 months1 Treatment naïve or recurrent/refractory disease appropriate for systemic treatment RINGSIDE is the Largest Phase 3 Study in Desmoid Tumors Design consistent with prior registrational trials Key Endpoints Primary: Progression-free survival2 (PF
Slide 10: Varegacestat Achieved Primary Endpoint
Varegacestat Achieved Primary Endpoint 84% Reduction in the Risk of Progression or Death vs Placebo Progression-Free Survival: HR 0.16; 95% CI: 0.071, 0.375; p < 0.0001
Slide 11: Varegacestat Demonstrates Robust Antitumor Activity
Par 56% ORR With Varegacestat vs 9% With Placebo (p<0.0001) -83% Median Best Percent Change in Tumor Volume With Varegacestat vs +11% With Placebo -83% Best Percent Change in Tumor Size with Varegacestat PR Varegacestat Demonstrates Robust Antitumor Activity PD
Slide 12: Varegacestat Was Generally Well-tolerated With a Manageable Safety Profile
Varegacestat was generally well-tolerated, with a manageable safety profile consistent with the GSI class of medicines The most common adverse events for participants in the treatment arm were diarrhea (82%), fatigue (44%), rash (43%), nausea (35%) and cough (34%) Most events were grade 1 or 2 55.6%
Slide 13: Elevating an Established Class and Solidifying the Role of GSIs in Desmoid Tumor Treatment
Elevating an Established Class and Solidifying the Role of GSIs in Desmoid Tumor Treatment ORR (%) 2018 2023 2025 Sorafenib 400mg Once Daily Oral NCT02066181; N=87 Nirogacestat 150 mg Twice-Daily Oral DeFi; n=142 Varegacestat 1.2mg Once-Daily Oral RINGSIDE; N=156 TKI Era GSI Era Phase 3 Studies in D
Slide 14: Launch Strategy
Launch Strategy Become Standard of Care treatment of Desmoid Tumors START Drive patient initiation on varegacestat SUPPORT Sustained benefit and adherence with a once-daily treatment SCALE Efficiently expand reach across the community through treatment center growth GSI Non-GSI Treatment 10-11k Acti
Slide 15: IM-1021: ROR1 ADC
IM 1021 ROR1 ADC
Slide 16: HC74 is a TOP1i Payload Designed to Overcome Fundamental Limitations of Existing Technology
HC74 is a TOP1i Payload Designed to Overcome Fundamental Limitations of Existing Technology Unstable linker Natural payloads High toxicity Stable peptide linker Synthetic payloads Narrow therapeutic window Improved therapeutic index Susceptible to resistance Limited bystander effect Improved therape
Slide 17: IM-1021: Potential Best-in-Class ROR1 ADC
IM-1021: Potential Best-in-Class ROR1 ADC Starting dose is 2 mg/kg of adjusted ideal bodyweight (AIBW) 2. Data sources: TCGA data (solid tumors and DLBCL) from UCSC Xena, version 2016-09-03. Blueprint data (MCL and CLL) from the Blueprint consortium, version 20160816. ROR1 Receptor with oncofetal ex
Slide 18: IM-1021 Preclinical Activity Supports Development in Lymphoma and Solid Tumors
IM-1021 Preclinical Activity Supports Development in Lymphoma and Solid Tumors IM-1021 Achieves Tumor Regressions in Jeko-1 MCL Model IM-1021 Achieves 8/8 CRs at 2.5 mg/kg in NSCLC PDX Model
Slide 19: Clinical Development Plan: Rapid Establishment of PoC
Clinical Development Plan: Rapid Establishment of PoC to Enable Pivotal Studies Across Multiple Indications DL1: 2 mg/kg AIBW DL2 DL3 DL4 DL5 Part A: Dose Escalation Part B: Indication-Specific Dose Expansion DL-Y DL-X Indication Cohort B1 DL-Y DL-X DL-Y DL-X Indication Cohort B2 Indication Cohort B
Slide 20: HC74 Platform
HC74 Platform Ql Immunome”
Slide 21: HC74's Low Efflux Potential and High Permeability Lead to Improved Properties
HC74’s Low Efflux Potential and High Permeability Lead to Improved Properties Superior HC74 cytotoxic activity across 89 cell lines High HC74 permeability2 drives superior bystander effect Low HC74 efflux potential1 overcomes payload resistance ADC Bystander Cytotoxicity4 Payload Cytotoxicity3 N =
Slide 22: Sensitivity to Efflux Meaningfully Limits the Clinical Efficacy of Existing TOP1i ADCs
Sensitivity to Efflux Meaningfully Limits the Clinical Efficacy of Existing TOP1i ADCs High P-gp Expression Correlates With Lower ORR and PFS in HER2+ CRC Patients Treated With T-DXd2 Schematic created with BioRender.com Sienna et al. Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd)
Slide 23: HC74 ADC Shows Activity in a CRC Model Refractory to Other TOP1i Agents
HCT-15 is a P-gp High Colorectal Model HCT-15 is Refractory to T-DXd but Sensitive to T-HC74 HCT-15 is Refractory to Irinotecan but Sensitive to T-HC74 HC74 ADC Shows Activity in a CRC Model Refractory to Other TOP1i Agents Source: Zhang et al., AACR-NCI-EORTC International Conference on Molecular T
Slide 24: HC74 ADC Demonstrates Superior Bystander Activity vs. DXd ADC
HC74 ADC Demonstrates Superior Bystander Activity vs. DXd ADC Potential for Greater HC74 Efficacy in Target Heterogenous Tumors NCI-H292 Bystander Model (75% TROP2+; 25% TROP2 KO) Clonal Preclinical Models Do Not Capture Expression Heterogeneity Source: Zhang et al., AACR-NCI-EORTC International Con
Slide 25: Expanding the Universe of ADC Targets
Expanding the Universe of ADC Targets Targets: Prioritize targets with compelling tumor biology and no approved ADCs. Focus on dynamic receptors that drive efficient ADC payload delivery Antibodies: Optimize and evaluate as ADCs Technology: Proprietary HC74 TOP1i payload designed to achieve wide the
Slide 26: IM-1617: Potential First-in-Class ADC for Multiple Solid Tumor Indications
IM-1617: Potential First-in-Class ADC for Multiple Solid Tumor Indications IM-1617 efficacy IM-1617 Target mRNA Expression (Log2 TPM+1) No IM-1617 efficacy Target Expression In Major Indications Corresponds to CDX Models Where IM-1617 Showed Activity IM-1617 Showed Activity In PDX Models That Are Re
Slide 27: Robust Pipeline of Preclinical Candidates Pursuing Undisclosed Solid Tumor Targets
Robust Pipeline of Preclinical Candidates Pursuing Undisclosed Solid Tumor Targets Solid tumor model Anticipated 2026 IND Submissions Additional Candidates IM-1617 ADC-U10 IM-1340 IM-1335 ADC-U11 ADC-U12
Slide 28: IM-3050: FAP-Targeted Radioligand Therapy
IM-3050 FAP-Targeted Radioligand Therapy
Slide 29: IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential
IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential Tumor Regression in U87MG Model No Weight Loss Observed Potential Best-in-Class Characteristics Sub-nanomolar affinity High specificity Radiostability Superior tumor retention and tumor absorbed dose in vivo Preclinical activity and toler
Slide 30: Company Overview
4) Immunome Company Overview
Slide 31: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Chief Executive Officer and Founder, Seagen (1998-2022) Grew company to $2B+ revenue (2022) leading to $43B acquisition Led development of 4 FDA-approved therapeutics Raised over $1B in public and private capital Oversaw acquisition and int
Slide 32: Accelerating the Pursuit of Breakthrough Oncology Therapies: Anticipated Milestones
Varegacestat NDA Submission Planned 2Q26 IM-1021 Ph1 Data 2026 Novel solid-tumor targeted ADCs ROR1 ADC Gamma Secretase Inhibitor Positive RINGSIDE Phase 3 topline data IM-1617 IND 2026 IM-1340 IND 2026 IM-1335 IND 2026 ADC portfolio including the HC74 platform represents substantial value Varegaces